Christine Willgoos litigates patent actions on behalf of pharmaceutical and biotechnology companies, leading trial and appellate teams in Hatch-Waxman and biologic drug litigation, often involving blockbuster drugs. Ms. Willgoos is an accomplished courtroom advocate with significant experience, including trials and appeals, preliminary injunctions, oral arguments and Markman hearings. She has handled cases in genetics, molecular biology, biochemistry and drug development, including those concerning humanized antibody technology, recombinant DNA vectors, antidepressant drugs and dermatologic drugs. Her work extends across other industries as well, including medical devices, semiconductors, telecommunications and electronics.

Among her most notable work, Ms. Willgoos secured a preliminary injunction and trial victory for the plaintiff, the holder of the patent for the innovator drug, in Hatch-Waxman litigation. She currently represents clients in cases concerning immunoassay technology, cancer drugs and multiple sclerosis drugs.

In addition to litigation, Ms. Willgoos counsels clients in business and legal matters relating to patent portfolios, including antitrust, patent prosecution, life cycle management and regulatory issues.